A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma.

Trial Profile

A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2011

At a glance

  • Drugs Docetaxel; SGN-15
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2011 Actual end date (Apr 2003) added as reported by ClinicalTrials.gov.
    • 13 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top